Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x100px

Collaboration › Details

Immatics–Leucadia: investor conference, 202209 supply service Immatics at Jefferies Cell and Genetic Medicine Summit 2022

	Period	2022-09-29 � 2022-09-30
	Region	New York, NY
	Country	United States (USA)
	Partner, 1st	Immatics N.V. (Nasdaq: IMTX)
	Partner, 2nd	Jefferies LLC
	Group	Leucadia (Group)
	Source	Immatics N.V.. (8/9/22). "Press Release: Immatics Announces Second Quarter 2022 Financial Results and Business Update". Tübingen & Houston, TX.

Record changed: 2022-09-05

Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

More documents for Immatics (Group)

[1] Immatics N.V.. (10/24/23). "Press Release: Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy". Houston, TX & Tübingen....
[2] Immatics N.V.. (9/11/23). "Press Release: Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics". Cambridge, MA & Tübingen....
[3] Immatics N.V.. (7/24/23). "Press Release: Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb". Tübingen & Houston, TX....
[4] MicrofluidX Ltd.. (5/2/23). "Press Release: MicrofluidX and Immatics Working Together on Automated End-to-End Bioprocessing for TCR-T Therapies". Stevenage & Houston, TX....
[5] AiCuris Anti-infective Cures AG. (9/1/22). "Press Release: AiCuris Appoints Experienced Business Leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer". Wuppertal....
[6] Immatics N.V.. (8/23/22). "Press Release: Immatics Announces First Cancer Patient Treated with Second-generation ACTengine TCR-T Candidate IMA203CD8 Targeting PRAME". Houston, TX & Tübingen....
[7] Immatics N.V.. (8/9/22). "Press Release: Immatics Announces Second Quarter 2022 Financial Results and Business Update". Tübingen & Houston, TX....
[8] Immatics N.V.. (6/7/22). "Press Release: Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer". Tübingen, Houston, T...
[9] Immatics N.V.. (6/2/22). "Press Release: Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs". Tübingen, Houston, TX & New York, NY....
[10] Immatics N.V.. (3/23/22). "Press Release: Immatics Announces Full Year 2021 Financial Results and Corporate Update". Tübingen & Houston, TX....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)